Skip to main content
. 2011 May;31(5):433–440. doi: 10.1089/jir.2010.0054

FIG. 3.

FIG. 3.

Serum samples from melanoma patients were analyzed for VEGFa expression at day 1 (pretreatment), day 8, and day 29 after IFNb-1a treatment. The level of VEGFa was determined using the Luminex multi-analyte technology. A decrease in VEGFa (*P < 0.03) was identified at day 29. All patients received 22 × 106 IU/m2 on days 1–14 and 18 × 106 IU/m2 on days 15–29.